Antipsychotic potential of CCK-based treatments: An assessment using the prepulse inhibition model of psychosis

Neuropsychopharmacology

Volumn 20, Issue 2, 1999, Pages 141-149

  Feifel, David ^a   Reza, Tammi ^a   Robeck, Stephanie ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CCK; Dopamine; Prepulse inhibition; Schizophrenia; Sensorimotor gating

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; AMPHETAMINE; CERULETIDE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; DEVAZEPIDE; HALOPERIDOL; TETRAGASTRIN;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; LOCOMOTION; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CAERULEIN; CHOLECYSTOKININ; GASTROINTESTINAL AGENTS; HALOPERIDOL; INJECTIONS, SUBCUTANEOUS; MALE; MOTOR ACTIVITY; PSYCHOTIC DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CHOLECYSTOKININ; STARTLE REACTION; TETRAGASTRIN;

EID: 0033080743     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00041-4     Document Type: Article

References (44)

1. Albus M. Cholecystokinin. Prog Neuro-Psychopharmacol Biol Psychiat. 12:1988;S5-S21.
2. Beinfeld M.D., Garver D.L. Concentration of cholecystokinin in cerebrospinal fluid is decreased in psychosis. Relationship to symptoms and drug response Prog Neuropsychopharmacol Biol Psychiat. 15:1991;601-609.
3. Braff D.L., Geyer M.A. Sensorimotor gating and schizophrenia. Human and animal model studies Arch Gen Psychiat. 47:1990;181-188.
4. B sites. Neuroreport. 3:1992;909-912.
5. Butler R.W., Jenkins M.A., Geyer M.A., Braff D.L. Wisconsin card sorting deficits and diminished sensorimotor gating in a discrete subgroup of schizophrenic patients. Tamminga C.A., Schulz S.C. Advances in Neuropsychiatry and Psychopharm, Vol 1. Schizophrenia Research:1991;163-168 Raven Press, New York.
6. Cadenhead K.S., Geyer M.A., Braff D.L. Impaired startle prepulse inhibition and habituation in schizotypal patients. Am J Psychiat. 150:1993;1862-1867.
7. Crawley J.N., Hays S.E., Paul S.M. Vagotomy abolishes the inhibitory effects of cholecystokinin on rat exploratory behaviors. Eur J Pharmcol. 73:1981;379-380.
8. Crawley J.N., Schwaber J.S. Abolition of the behavioral effects of cholecystokinin following bilateral radiofrequency lesions of the parvocellular subdivision of the nucleus tractus solitarius. Brain Res. 295:1984;289-299.
9. Crawley J.N. Cholecystokinin-dopamine interactions. TINS. 165:1991;6147-6151.
10. Crawley J.N., Corwin R.L. Biological actions of cholecystokinin. Peptides. 15:1994;731-755.
11. Csonka E., Fekete M., Nagy G.et al. Anxiogenic effect of cholecystokinin in rats. Penke B., Toroke A. Peptides, Chemistry, Biology, Interactions with Proteins. 1988;249-252 Walter de Druyter, Berlin.
12. Feifel D., Swerdlow N.R. The modulation of sensorimotor gating deficits by mesolimbic cholecystokinin. Neurosci Lett. 229:1997;5-8.
13. Graham F. The more-or-less startling effects of weak prestimuli. Psychophysiology. 12:1975;238-248.
14. Hommer D.W., Pickar D., Crawley J.N., Weingartner H., Paul S.M. The effects of cholecystokinin-like peptides in schizophrenics and normal human subjects. Ann NY Acad Sci. 448:1985;542-552.
15. Itoh H., Tanoue S., Yagi G., Tateyama M., Kmisada M., Fujii Y., Takamiya M., Nakajima S. Clinical study on the psychotropic effects of caerulein - An open clinical trial in chronic schizophrenic patients. Keio J Med. 31:1982;71-95.
16. Itoh T., Murai S., Masuda Y., Abe E., Ohkubo N., Itsukaichi O., Shoji S. Pharmacological properties of ceruletide in the vertical and horizontal locomotor activities of mice. Pharmacol Biochem Behav. 43:1992;571-576.
17. Kihara T., Ikeda M., Matsubara K., Matsushita A. Differential effects of ceruletide on amphetamine-induced behaviors and regional dopamine release in the rat. Eur J Pharmacol. 230:1993;271-277.
18. Kihara T., Masato I., Nobuhiro I., Akira M. Ceruletide, a CCK-like peptide, attenuates dopamine release from the rat striatum via a central site of action. Brain Res. 558:1992;270-276.
19. Lee M.C., Schiffman S.S., Pappas T.N. Role of neuropeptides in the regulation of feeding behavior. A review of cholecystokinin, bombesin, neuropeptide Y, and galanin Neurosci Biobehav Rev. 18:1994;313-323.
20. Lotstra F., Verbanck P., Mendlewicz J., Vanderhaeghen J.J. No evidence of antipsychotic effect of caerulein in schizophrenic patients free of neuroleptics. a double-blind cross-over study Biol Psychiat. 6:1984;877.
21. Mansbach R.S., Geyer M.A., Braff D.L. Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology. 94:1988;507-514.
22. Mansbach R.S., Lorenz D.N. Cholecystokinin (CCK-8) elicits prandial sleep in rats. Physiol Behav. 30:1983;179-183.
23. Masuda Y., Murai S., Saito H., Abe E., Itoh T. Delayed suppressive effect of a low dose of caerulein on the grooming behavior induced by the D1-receptor agonist SKF 38393. Japan J Pharmacol. 2:1992;141-144.
24. McGhie A., Chapman J. Disorder of attention and perception in early schizophrenia. Brit J Med Psychol. 34:1961;102-116.
25. Moroji T., Watanabe N., Aoki N., Itoh S. Antipsychotic effects of caerulein, a decapeptide chemically related to cholecystokinin octapeptide, on schizophrenia. Int Pharmacopsychiat. 17:1982;255-273.
26. Nair N.P., Bloom D.M., Nestoros J.N. Cholecystokinin appears to have antipsychotic properties. Prog Neuro-Psychopharmacol Biol Psychiat. 6:1982;509-512.
27. Nair N.P., Bloom D.M., Debonnel G., Schwartz G., Mosticyan S. Cholecystokinin-octapeptide in chronic schizophrenia. A double-blind placebo-controlled study Prog Neuro-Psychopharmacol Biol Psychiat. 8:1984;711-714.
28. Nair N.P.V., Lal S., Bloom D.M. Cholecystokinin and schizophrenia. Prog Brain Res. 65:1986;237-257.
29. Nemeroff C.B., Bissette G. Neuropeptides, dopamine, and schizophrenia. Ann NY Acad Sci. 668:1992;273-291.
30. Peselow E., Angrist B., Sudilovsky A., Corwin J., Siekierski J., Trent F., Rotrosen J. Double-blind controlled trials of cholecystokinin octapeptide in neuroleptic-refractory schizophrenia. Psychopharmacology. 91:1987;80-84.
31. Schalling M., Friberg K., Seroogy K. Analysis of expression of cholecystokinin in dopamine cells in the ventral mesencephalon of several species and human with schizophrenia. Proc Natl Acad Sci USA. 87:1990;8427-8431.
32. Schell A.M. Attentional modulation of startle in psychosis-prone college students. Psychophysiology. 32:1995;266-273.
33. Schwarzkopf S.B., McCoy L., Smith D.A., Boutros N.N. Test-retest reliability of prepulse inhibition of the acoustic startle response. Biol Psychiat. 34:1993;896-900.
34. Swerdlow N.R., Caine S.B., Braff D.L., Geyer M.A. The neural substrates of sensorimotor gating of the startle reflex. A review of recent findings and their implications J Psychopharmacol. 6:1992;176-190.
35. Swerdlow N.R., Braff D.L., Taaid N., Geyer M.A. Assessing the validity of an animal model of sensorimotor gating deficits in schizophrenia. Arch Gen Psychiat. 51:1994;139-154.
36. Swerdlow N.R., Geyer M.A. Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharm Biochem Beh. 44:1993;741-744.
37. Tamminga C.A., Littman R.L., Alphs L.D., Chase T.N., Thaker G.K., Wagman A.M. Neuronal cholecystokinin and schizophrenia. pathogenic and therapeutic studies Psychopharmacology. 88:1986;387-391.
38. Vaccarino F.J. Nucleus accumbens dopamine-CCK interactions in psychostimulant reward and related behaviors. Neurosci Biobehav Rev. 18:1994;207-214.
39. Van Ree J.M., Gaffori O., De Weid D. In rats, the behavioral profile of CCK-8 and related peptides resembles that of antipsychotic agents. Eur J Pharmacol. 93:1983;63-78.
40. Van Ree J.M., Verhoeven W.M., Brouwer G.J., de Wied D. Ceruletide resembles antipsychotics in rats and schizophrenic patients. Preliminary report. Neuropsychobiology. 12:1984;4-8.
41. Vasar E., Harro J., Lang A., Pold A., Soosaar A. Differential involvement of CCK-A and CCK-B receptors in the regulation of locomotor activity in the mouse. Psychopharmacology (Berlin). 105:1991;393-399.
42. Verbanck P.M.P., Lotstra F., Gilles C., Linkowski P., Mendlewicz J., Vanderhaegen J.J. Reduced cholecystokinin immunoreactivity in cerebrospinal fluid of patients with psychiatric disorders. Life Sci. 34:1984;67-72.
43. Wang Z.J., Rao Z.R., Shi J.W. Tyrosine hydroxylase-, neurotensin-, or cholecystokinin-containing neurons in the nucleus tractus solitarii send projection fibers to the nucleus accumbens in the rat. Brain. 578:1992;347-350.
44. Zhang L.X., Smith M.A., Kim S.Y., Rosen J.B., Weiss S.R., Post R.M. Changes in cholecystokinin mRNA expression after amygdala kindled seizures. An in situ hybridization study Brain Res. 35:1996;278-284.